The recent data that the glycolytic regulator PFKFB3 controls vessel sprouting and its blockade promotes tumor vessel normalization [83] raise the question if strategies targeting EC metabolism could increase the response of cancer patients to current anticancer treatment and represent a complementary or alternative antiangiogenic approach. The gene discussed is PFKFB3; the disease is cancer.